Minnesota Oncology treated its first patient today on the St. Paul Cancer Center’s Nasseff CyberKnife. The CyberKnife® M-6 Robotic Radiosurgery System is a powerful, non-invasive and non-surgical precision treatment option for cancerous and noncancerous tumors and lesions. Brain, kidney, liver, pancreas, skull base, and spine tumors and lesions may qualify for CyberKnife treatment at Minnesota Oncology.
Nasseff CyberKnife is a part of John Nasseff NeuroScience Institute, part of Allina Health. Services are provided by Minnesota Oncology as well as the Virginia Piper Cancer Institute, also part of Allina Health. Minnesota Oncology radiation oncologists Dr. Ellen Bellairs, Dr. Kathryn Farniok, and Dr. Mark Palmer will treat patients with the CyberKnife M-6 System, the newest addition to Minnesota Oncology’s comprehensive radiation therapy treatment options.
“This CyberKnife produces better outcomes with less toxicity,” said Ellen Bellairs, MD, radiation oncologist with Minnesota Oncology and Nasseff CyberKnife co-director. “This is the most significant advancement in radiation therapy that I have seen in 18 years of practice. It’s refreshing to be able to offer it to patients.”
Specialists at Nasseff CyberKnife have years of experience in treating cancerous and non-cancerous tumors throughout the body and head. The CyberKnife System is FDA approved to treat tumors and lesions anywhere in the body.
CyberKnife treatment may not be appropriate for all conditions and patients, but we invite you to contact our caring and expert staff to help determine if CyberKnife is right for you. Call us at 651-241-4646.
Learn more about Minnesota Oncology’s Radiation Therapy treatment options here.